1. Home
  2. JBL vs UTHR Comparison

JBL vs UTHR Comparison

Compare JBL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JBL
  • UTHR
  • Stock Information
  • Founded
  • JBL 1966
  • UTHR 1996
  • Country
  • JBL United States
  • UTHR United States
  • Employees
  • JBL N/A
  • UTHR N/A
  • Industry
  • JBL Electrical Products
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • JBL Technology
  • UTHR Health Care
  • Exchange
  • JBL Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • JBL 21.7B
  • UTHR 20.7B
  • IPO Year
  • JBL 1993
  • UTHR 1999
  • Fundamental
  • Price
  • JBL $213.58
  • UTHR $446.81
  • Analyst Decision
  • JBL Strong Buy
  • UTHR Buy
  • Analyst Count
  • JBL 9
  • UTHR 12
  • Target Price
  • JBL $228.78
  • UTHR $495.08
  • AVG Volume (30 Days)
  • JBL 1.2M
  • UTHR 598.0K
  • Earning Date
  • JBL 12-17-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • JBL 0.15%
  • UTHR N/A
  • EPS Growth
  • JBL N/A
  • UTHR 16.08
  • EPS
  • JBL 5.92
  • UTHR 26.38
  • Revenue
  • JBL $29,802,000,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • JBL $6.68
  • UTHR $13.68
  • Revenue Next Year
  • JBL $5.65
  • UTHR $5.63
  • P/E Ratio
  • JBL $36.10
  • UTHR $17.02
  • Revenue Growth
  • JBL 3.18
  • UTHR 13.50
  • 52 Week Low
  • JBL $108.66
  • UTHR $266.98
  • 52 Week High
  • JBL $237.14
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • JBL 51.20
  • UTHR 56.88
  • Support Level
  • JBL $209.15
  • UTHR $430.02
  • Resistance Level
  • JBL $220.55
  • UTHR $456.41
  • Average True Range (ATR)
  • JBL 7.86
  • UTHR 14.19
  • MACD
  • JBL 0.57
  • UTHR 0.19
  • Stochastic Oscillator
  • JBL 55.63
  • UTHR 51.88

About JBL Jabil Inc.

Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: